For pharma and biotech leaders
Agree on what your AI pilot must prove.
Finance, procurement and implementation may support the same idea for different reasons. Work through what each owner needs the pilot to establish.
Free case analyses and new-report announcements by email.
- Who authorizes the next step?
- What must the test establish?
- What would change the plan?
Before funding the test
Would everyone approve the same pilot?
The group supports an AI partnership. Finance wants a useful business comparison. Procurement needs permitted sources and clear responsibilities. The implementation owner needs a workable evaluation. A shared expression of support does not resolve those different decisions.
Finance
What are we funding, and what comparison will inform the next investment?
Procurement
Which permissions, terms and partner responsibilities must be established?
Implementation
Who owns the workflow and the evaluation, including checking and rework?
A useful pilot charter connects the purpose of the test to the evidence each owner needs.
“What would make this proposal difficult for your team to approve or use?”
Make the reasoning visible.
Work through a question, the available evidence and what to do next.
Structured analytic techniques, in use
Key Assumptions Check
Does “success” mean the same thing to each owner?
How to examine the question
Write down what finance, procurement and implementation each expect the pilot to establish. Then distinguish a confirmed condition from a premise still being assumed.
What the evidence establishes
A sponsor supports the idea.
What has not been confirmed
Funding authority and source permissions have not yet been confirmed.
Assessment
Important conditions remain open
How the decision changes
Name the missing approvals and their owners before asking the group to authorize the pilot.
Competing Hypotheses
Would faster writing change the workflow’s main burden?
The explanations to compare
In the competitive-briefing example, drafting is only a possible explanation. Repeated searches for the same documents and time spent checking sources suggest another place to investigate.
What the evidence establishes
The work records show repeated source preparation.
What the evidence does not establish
They do not establish that drafting is the main cause of delay.
Assessment
The evidence points to a different test
How the decision changes
Compare a focused search test with the drafting proposal. If completed briefs are waiting for review, investigate that delay first.
Quality of Information Check
Does the work log cover the outcome finance cares about?
How to check the evidence
A log that ends when a first draft is submitted cannot establish the entire approval cycle. Check where the evidence starts and ends before using it to justify an investment.
What the evidence covers
Pre-submission work is recorded.
What the evidence leaves open
The time from the original request to final approval, including later checking, is not fully recorded.
Assessment
The business outcome still needs a measure
How the decision changes
Track time spent searching and checking separately. Also measure the time from the request to final approval. Agree which findings would justify the next investment.
These examples adapt structured analytic techniques described by the U.S. Government (2009).
The partnership landscape
89%
What should you build together?
In IQVIA’s May 2025 survey of 107 senior commercial leaders, 89% said their organizations were already co-developing AI with external vendors or actively considering it (Kotakonda & Awasthi, 2025).
The finding describes these respondents, rather than all life-sciences companies. For a sponsor and provider considering a test, the practical question is which problem to tackle together and what each side needs to learn.
From the current issue
Deal Formation
From Interest to a Pilot Decision
Written for sponsors and AI providers, Report 01 follows a commercial partnership from initial interest through the pilot decision. Its examples focus on U.S. pharmaceutical commercial operations.
48-page PDF. Eight structured analytic techniques. $99 for one named reader.
The continuing series
Bring a clearer basis to the next decision.
Subscribe to Deal Design Intelligence for practical cases, analysis and new-report announcements. Begin with the decisions behind enterprise AI partnerships in life sciences.
New analysis as it is published. Full reports are sold separately.
Strategic areas are optional. Leave them blank for the current enterprise AI partnership series, or select only the areas you want. Broader areas are proposed future coverage.
The sign-up form is loading.
Read how we handle information.